|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bernstein E, Caudy AA, Hammond SM and
Hannon GJ: Role for a bidentate ribonuclease in the initiation step
of RNA interference. Nature. 409:363–366. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bahubeshi A, Tischkowitz M and Foulkes WD:
miRNA processing and human cancer: DICER1 cuts the mustard. Sci
Transl Med. 3:111ps462011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen X, Li WF, Wu X, Zhang HC, Chen L,
Zhang PY, Liu LY, Ma D, Chen T, Zhou L, et al: Dicer regulates
non-homologous end joining and is associated with chemosensitivity
in colon cancer patients. Carcinogenesis. 38:873–882. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sha LY, Zhang Y, Wang W, Sui X, Liu SK,
Wang T and Zhang H: MiR-18a upregulation decreases Dicer expression
and confers paclitaxel resistance in triple negative breast cancer.
Eur Rev Med Pharmacol Sci. 20:2201–2208. 2016.PubMed/NCBI
|
|
8
|
Chen JC, Su YH, Chiu CF, Chang YW, Yu YH,
Tseng CF, Chen HA and Su JL: Suppression of Dicer increases
sensitivity to gefitinib in human lung cancer cells. Ann Surg
Oncol. 21 Suppl 4:S555–S563. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu Y, Cai L, Guo J, Chen N, Yi X, Zhao Y,
Cai J and Wang Z: Depletion of Dicer promotes epithelial ovarian
cancer progression by elevating PDIA3 expression. Tumour Biol.
37:14009–14023. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Merritt WM, Lin YG, Han LY, Kamat AA,
Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick
AM, et al: Dicer, Drosha, and outcomes in patients with ovarian
cancer. N Engl J Med. 359:2641–2650. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kuang Y, Cai J, Li D, Han Q, Cao J and
Wang Z: Repression of Dicer is associated with invasive phenotype
and chemoresistance in ovarian cancer. Oncol Lett. 5:1149–1154.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J,
Xiao L and Wang Z: Overexpression of EZH2 contributes to acquired
cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Cancer Biol Ther. 10:788–795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Holzer AK and Howell SB: The
internalization and degradation of human copper transporter 1
following cisplatin exposure. Cancer Res. 66:10944–10952. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ahsan A, Hiniker SM, Ramanand SG, Nyati S,
Hegde A, Helman A, Menawat R, Bhojani MS, Lawrence TS and Nyati MK:
Role of epidermal growth factor receptor degradation in
cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res.
70:2862–2869. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai L, Wang Z and Liu D: Interference with
endogenous EZH2 reverses the chemotherapy drug resistance in
cervical cancer cells partly by up-regulating Dicer expression.
Tumour Biol. 37:6359–6369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawahara K, Nakayama H, Nagata M, Yoshida
R, Hirosue A, Tanaka T, Nakagawa Y, Matsuoka Y, Kojima T, Takamune
Y, et al: A low Dicer expression is associated with resistance to
5-FU-based chemoradiotherapy and a shorter overall survival in
patients with oral squamous cell carcinoma. J Oral Pathol Med.
43:350–356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bu Y, Lu C, Bian C, Wang J, Li J, Zhang B,
Li Z, Brewer G and Zhao RC: Knockdown of Dicer in MCF-7 human
breast carcinoma cells results in G1 arrest and increased
sensitivity to cisplatin. Oncol Rep. 21:13–17. 2009.PubMed/NCBI
|
|
19
|
Nakagawa A, Shi Y, Kage-Nakadai E, Mitani
S and Xue D: Caspase-dependent conversion of Dicer ribonuclease
into a death-promoting deoxyribonuclease. Science. 328:327–334.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Swahari V, Nakamura A, Baran-Gale J,
Garcia I, Crowther AJ, Sons R, Gershon TR, Hammond S, Sethupathy P
and Deshmukh M: Essential function of dicer in resolving DNA damage
in the rapidly dividing cells of the developing and malignant
cerebellum. Cell Rep. 14:216–224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aubrey BJ, Kelly GL, Janic A, Herold MJ
and Strasser A: How does p53 induce apoptosis and how does this
relate to p53-mediated tumour suppression? Cell Death Differ.
25:104–113. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mollereau B and Ma D: The p53 control of
apoptosis and proliferation: Lessons from Drosophila. Apoptosis.
19:1421–1429. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gonzalez VM, Fuertes MA, Alonso C and
Perez JM: Is cisplatin-induced cell death always produced by
apoptosis? Mol Pharmacol. 59:657–663. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Domcke S, Sinha R, Levine DA, Sander C and
Schultz N: Evaluating cell lines as tumour models by comparison of
genomic profiles. Nat Commun. 4:21262013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tran TQ, Lowman XH, Reid MA,
Mendez-Dorantes C, Pan M, Yang Y and Kong M: Tumor-associated
mutant p53 promotes cancer cell survival upon glutamine deprivation
through p21 induction. Oncogene. 36:1991–2001. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu C, Xie Z and Peng Q: MiRNA-107 enhances
chemosensitivity to paclitaxel by targeting antiapoptotic factor
Bcl-w in non small cell lung cancer. Am J Cancer Res. 7:1863–1873.
2017.PubMed/NCBI
|
|
27
|
Wu G, Wang J, Chen G and Zhao X:
microRNA-204 modulates chemosensitivity and apoptosis of prostate
cancer cells by targeting zinc-finger E-box-binding homeobox 1
(ZEB1). Am J Transl Res. 9:3599–3610. 2017.PubMed/NCBI
|
